Gilead, Bristol bow to superiority of CAR-T treatments for blood cancer

VSCompetitive, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated additional benefits for patients with B cell lymphoma at an earlier stage of treatment than they are currently used for. . But is one better than the other?

The results of the successful clinical trials, dubbed ZUMA-7 and TRANSFORM by Gilead and Bristol, respectively, are presented this weekend at the annual meeting from the American Society of Hematology. Collectively, the data is likely to expand the use of these CAR-T therapies – Yescarta from Gilead and Breyanzi from Bristol – and drive higher sales for both companies.

Unlock this article by subscribing to STAT + and enjoy your first 30 days free!


What is that?

STAT + is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news on Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, as well as healthcare disruptions in Silicon Valley and beyond.

What is included?

  • Daily reporting and analysis
  • Industry’s most comprehensive coverage from a powerful team of journalists
  • Newsletters reserved for subscribers
  • Daily newsletters to keep you informed of the most important industry news of the day
  • STAT + conversations
  • Weekly opportunities to engage with our journalists and leading industry experts in live video chats
  • Exclusive industry events
  • Premium access to subscriber-only networking events nationwide
  • The best reporters in the industry
  • The most reliable and most connected newsroom in the healthcare industry
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.

Comments are closed.